Huanglian, a Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells Journal Article


Authors: Li, X. K.; Motwani, M.; Tong, W.; Bornmann, W.; Schwartz, G. K.
Article Title: Huanglian, a Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells
Abstract: Huanglian is an herb that is widely used in China for the treatment of gastroenteritis. We elected to determine whether huanglian could inhibit tumor cell growth by modulating molecular events directly associated with the cell cycle. Huanglian inhibited tumor growth and colony formation of gastric, colon, and breast cancer cell lines in a time- and dose-dependent manner. Cell growth was completely inhibited after 3 days of continuous drug exposure to 10 μg/ml of herb. This degree of growth inhibition was significantly greater than that observed with berberine, the major constituent of the herb. The inhibition of cell growth by huanglian was associated with up to 8-fold suppression of cyclin B1 protein. This resulted in complete inhibition of cdc2 kinase activity and accumulation of cells in G2. The mRNA expression of cyclin B1 was not changed after huanglian treatment. There was no change in the protein expression of cyclins A or E. Therefore, the effect of huanglian on inhibiting tumor growth seems to be mediated by the selective suppression of cyclin B1, which results in the inhibition of cdc2 kinase activity. Inhibition of cyclin dependent kinase (cdk) activity is emerging as an attractive target for cancer chemotherapy. Huanglian represents a class of agents that can inhibit tumor cell growth by directly suppressing the expression of a cyclin subunit that is critical for cell cycle progression. These results indicate that traditional Chinese herbs may represent a new source of agents designed for selective inhibition of cyclin dependent kinases in cancer therapy.
Keywords: controlled study; protein expression; unclassified drug; human cell; antineoplastic agents; mitosis; cell division; gene expression; transcription, genetic; tumor cells, cultured; cancer inhibition; drug mechanism; messenger rna; rna, messenger; cancer cell; breast carcinoma; short survey; drugs, chinese herbal; traditional medicine; chinese herb; chromatography, high pressure liquid; cyclin b1; colon carcinoma; cyclin a; cyclin b; colony-forming units assay; stomach carcinoma; protein kinase; cyclin e; g2 phase; gastroenteritis; cdc2 protein kinase; berberine; humans; human; priority journal; huanglian
Journal Title: Molecular Pharmacology
Volume: 58
Issue: 6
ISSN: 0026-895X
Publisher: The American Society for Pharmacology and Experimental Therapeutics  
Date Published: 2000-12-01
Start Page: 1287
End Page: 1293
Language: English
PUBMED: 11093765
PROVIDER: scopus
DOI: 10.1124/mol.58.6.1287
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. William Bornmann
    107 Bornmann
  2. William Ping-Yiu Tong
    122 Tong
  3. Gary Schwartz
    358 Schwartz
  4. Monica V Motwani
    36 Motwani
  5. Xiaokui   Li
    8 Li